{"id":"W4385839624","doi":"10.1038/s41591-023-02528-9","title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":564,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Genentech; Cilag; Astellas Pharma; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Adaptive Biotechnologies; Karyopharm Therapeutics; AstraZeneca España; Sanofi; Legend Biotech; Celgene; Amgen; Pfizer","keywords":"Medicine; Neutropenia; Dosing; Internal medicine; Adverse effect; Clinical endpoint; Multiple myeloma; Anemia; Cytokine release syndrome; Gastroenterology; Refractory (planetary science); Lenalidomide; Clinical trial; Surgery; Cancer; Chemotherapy; Immunotherapy; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003087562,0.0009545975,0.001371493,0.0002054468,0.0002369213,0.000794869,0.0005522278,0.0008877829,0.00230838],"category_scores_gemma":[0.000995634,0.0001924452,0.001075282,0.0002688609,0.000340571,0.0005088326,0.0002613951,0.001745156,0.0005607343],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006453131,"about_ca_system_score_gemma":0.0009767844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004763883,"about_ca_topic_score_gemma":0.00129683,"domain_scores_codex":[0.9993993,0.0003186098,0.00003215669,0.00007348257,0.00008261167,0.00009387984],"domain_scores_gemma":[0.9996338,0.00008623834,0.00009522391,0.00003079025,0.00003109831,0.0001228982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.56829,0.01987899,0.01113516,0.002988495,0.00352334,0.000760737,0.0004300087,0.006368261,0.0533123,0.001134561,0.03116842,0.3010097],"study_design_scores_gemma":[0.7739692,0.1530699,0.03761122,0.0003318172,0.001779496,0.000926166,0.00006289978,0.003882897,0.006267151,0.001247525,0.02078702,0.00006465341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9605983,0.02110049,0.001373148,0.002591029,0.0002676034,0.002728917,0.00381122,0.0003065579,0.00722271],"genre_scores_gemma":[0.9693975,0.007890866,0.00242035,0.003645614,0.0004223013,0.003383187,0.007941329,0.00008485041,0.004814053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003087562,"threshold_uncertainty_score":0.01632881,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04440612642337285,"score_gpt":0.3940585836265068,"score_spread":0.3496524572031339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}